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EFFICACY OF CELL SALVAGE IN NEONATES AND CHILDREN 
UNDERGOING CARDIAC SURGERY 
 
WILLIAM N. STEVENS 
ABSTRACT 
Background 
Cell salvage (CS) techniques are used to reduce exposure to allogeneic 
packed red blood cell (pRBC) transfusion in patients undergoing cardiac surgery. 
However, some studies suggest that inappropriate use of these techniques 
is associated with increased incidences of thrombocytopenia, 
excessive bleeding, and transfusion of non-red blood cell blood products, 
including fresh frozen plasma (FFP), cryoprecipitate, and platelets. Pediatric 
patients undergoing cardiac surgery are at higher risk for increased perioperative 
bleeding and blood product transfusion requirement. To date, limited evidence 
supports the use of CS to reduce pRBC transfusion in neonates and children 
undergoing cardiac surgery.   
Objectives 
 This study analyzed the efficacy of systematic use of CS in neonates and 
children undergoing cardiac surgery with cardiopulmonary bypass (CPB) 
compared to a historic cohort of children in whom CS was not used. Our primary 
endpoints included the incidences of pRBC, cryoprecipitate, and platelets 
transfusion occurring within 48 hours after CPB. 
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Methods 
We performed a retrospective medical chart review to study all neonates 
and children who underwent cardiac surgery with CPB between January 2013 
and December 2014 at Boston Children’s Hospital (BCH). Considering that CS 
has been systematically applied at BCH since January 2014, children were 
separated into a control group (before January 2014) and a CS group (after 
January 2014). Children treated with CS before January 
2014 were excluded. We used uni- and multivariable logistic regression analysis 
to assess the effect of CS on the odds of blood products transfusion.   
Results 
Among 1228 patients included in the analysis, 730 were included in 
the CS group and 498 in the control group. The results of our multivariate logistic 
regression analysis showed that age < 12 months (odds ratio (OR): 2.95, 95% 
confidence interval (CI): 2.26-3.84), American Society of Anesthesiologists 
Physical Status Classification (ASA) > 3 (OR: 2.95, 95% CI: 2.26-3.84), Risk 
Adjustment for Congenital Heart Surgery score (RACHS) > 3 (OR: 1.78, 95% CI: 
1.28-2.49), and the use of CS (OR: 0.57, 95% CI: 0.44-0.73) were good 
predictors for perioperative transfusion. Using univariable analysis, the use of CS 
was associated with a significant reduction in pRBC transfusion (OR: 0.76, 95% 
CI: 0.61-0.96, p = 0.021), but a significant increase in cryoprecipitate (OR: 1.37, 
95% CI: 1.08-1.76, p = 0.009) and platelets transfusions (OR: 1.37 95% CI: 1.08-
1.76, p = 0.004). However, after adjustment for age < 12 months, ASA > 3, and 
	  	   vii	  
RACHS > 3, the use of CS significantly reduced pRBC transfusion (OR: 0.57, 
95% CI: 0.44-0.73, p < 0.001), with no effect on cryoprecipitate (OR: 1.08, 95% 
CI: 0.83-1.41, p = 0.543) and platelets transfusions (OR: 1.05, 95% CI: 0.81-1.36, 
p = 0.694).    
Conclusion 
The use of CS in neonates and children undergoing cardiac surgery with 
CPB significantly reduced the incidence of pRBC transfusion. 
Although the systematic use of CS in adults has been associated with an 
increased incidence of non-pRBC transfusions, the use of CS in a high 
risk pediatric population (age < 12 months, ASA > 3, RACHS > 3) was 
associated with a 43% reduction of pRBC transfusion without any increases in 
cryoprecipitate and platelets transfusions.   
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INTRODUCTION 
 
 Neonates and children who undergo cardiac surgery with cardiopulmonary 
bypass (CPB) are at increased risk of perioperative bleeding, and blood product 
transfusion requirements (Guzzetta et al., 2015). In pediatric patients undergoing 
open heart surgeries, bleeding risk and blood products transfusion rates are 
related to age, with neonates being at higher risk (Williams et al., 1998). The 
perioperative coagulopathy observed in patients undergoing cardiac surgery with 
CPB is multifactorial and complex. Despotis et al. characterized CPB-induced 
coagulopathy by the following interactions: (i) hemodilution coagulopathy 
secondary to cardioplegia, the volume of CPB prime, and administration of fluids 
in the perioperative period, (ii) contact activation (activation of factor X and 
thrombin generation) due to tissue injury, tissue factor production, and activation 
of fibrinolytic pathways, and (iii) consumption coagulopathy due to thrombin, 
plasmin, and inflammation mediated processes (Despotis et al.,1999). All of 
these factors can generate a vicious cycle leading to increased coagulopathy and 
a systemic inflammatory response. In addition to coagulopathy, techniques used 
to promote anticoagulation using unfractionated heparin, reversal of heparin 
anticoagulation using protamine, and other physiological disturbances such as 
hypothermia, acidemia, and hypocalcemia, will increase the risk of bleeding 
(Paparella et al., 2004). 
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Although all of these mechanisms are observed in both adult and pediatric 
patients, there are increased risks of coagulopathy, perioperative bleeding, and 
transfusion requirements in children when compared with adults (Osthaus et al., 
2008). Risk factors for coagulopathy specific to children with congenital heart 
defects (CHD) include surgery in the newborn period, cyanotic CHD, and 
complex or repeat cardiac surgery. Cardiac operations in pediatric populations 
are inherently dangerous; surgeries are often long, performed at low 
temperatures, and require suture lines that can cover an extensive surface area 
of a patient with miniscule body size (Guzzetta et al., 2015). In addition, 
hemostatic abnormalities due to cardiac surgery are noted because of the 
necessary use of anticoagulants and the activation of clotting factors during 
surgery, creating a very complex hemostatic environment (Hartmann et al., 
2006). Indeed, some necessary clotting factors are either not effectively 
produced or activated by neonates and infants, minimizing the abilities of natural 
clotting and, therefore, increasing perioperative bleeding (Guzzetta and Miller, 
2011). For example, coagulation factors do not cross the placenta throughout 
gestation, and factors II, VII, XIII and fibrinogen are reduced to about 50% of 
normal adult values at birth (Pichler and Pichler, 2008). Neonatal platelet levels 
are similar to normal adult values at birth, but they seem to be hypoactive 
(Pichler and Pichler, 2008).  
 As a consequence of the summation of these factors, neonates and 
children have an increased and eminent need for four major hemostatic 
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transfusion products: packed red blood cells (pRBC), platelets, fresh frozen 
plasma (FFP), and cryoprecipitate (Guzzetta et al., 2015). pRBC are transfused 
to improve oxygen delivery to tissues in critically ill children when hemoglobin 
falls to a range of 7-9 grams per deciliter (Lacroix et al., 2007). Platelets 
recognize damaged blood vessels and form hemostatic thrombi to accelerate the 
process of coagulation (Rand et al., 2003), and are indicated when a patient 
exhibits thrombocytopenia secondary to hemorrhage (Sharma et al., 2011). FFP 
is the liquid portion of blood (Mayr, 2007). Plasma contains all coagulation factors 
and is used for reversal of anticoagulation changes that are often a surgical 
necessity (Sharma et al., 2011). Cryoprecipitate is a concentrated solution 
containing fibrinogen, fibronectin, von Willebrand factor, platelet microparticles, 
and clotting factors VIII and XIII (Callum et al., 2009). Because FFP contains all 
coagulation factors in, at best, physiologic concentrations, large volumes of 
plasma are required to significantly increase the plasmatic concentration in a 
bleeding patient (Chowdhury et al., 2004). For this reason, cryoprecipitate is 
prepared by centrifuging FFP and collecting the precipitate, and is transfused in 
patients with massive hemorrhaging because it contains significantly higher 
concentrations of fibrinogen and some other factors (Levy et al., 2012). 
Altogether, these blood products are transfused to return the hemostatic system 
in a distressed patient to homeostasis. 
In a study of 802 postoperative admissions to the cardiac intensive care 
unit (CICU) at Boston Children’s Hospital (BCH), 46 percent of patients who 
	  4 
required pRBC transfusion within the first 48 postoperative hours were younger, 
required a more complex cardiac surgery, and using risk scores, were diagnosed 
as more acutely ill than the 52 percent of patients who were not transfused 
(Salvin et al., 2011). Risk scores are important tools in preoperative assessment 
to describe patient-specific variables and create a uniform system for analysis 
(Geissler et al., 2000). American Society of Anesthesiologists Physical Status 
Classification (ASA) (Saklad, 1941; Haynes and Lawler, 1995) and Risk 
Adjustment for Congenital Heart Surgery score (RACHS) (Jenkins et al., 2002) 
are two examples of risk scores that assess patients for anesthetic and CHD 
procedures, respectively. This study also found that transfusion is associated 
with prolonged hospitalization, with the strongest association between the most 
transfused groups (Salvin et al., 2011). It is known that transfusion occurs in 
nearly half of all pediatric intensive care unit (ICU) patients (Bateman et al., 
2008), and it has been proposed that transfusion may have significant influences 
on overall morbidity and mortality after cardiac surgery (Guzzetta et al., 2015). 
Because a restrictive transfusion strategy has been found to be more efficacious 
than a liberal strategy (Lacroix et al., 2007), it is vital to identify risk factors for 
bleeding to apply a more contemplative and reasonable approach to the 
administration of blood products to patients.  
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Allogeneic transfusions 
The allogeneic transfusion, the transfer of blood products from the 
circulation of a donor to the circulation of a recipient (Learoyd, 2012), is one of 
the most common procedures performed in hospitals in the United States and is 
administered at a cost of billions of dollars each year (Anthes, 2015). 
Transfusions have experienced a dramatic growth in use and popularity among 
clinicians during the last century due to their reputation as an easy to use and 
readily available hemostatic therapy (Shander et al., 2013). Blood product 
transfusions are undoubtedly lifesaving measures in cases of severe hemorrhage 
or dangerously low hemoglobin levels (Murphy et al., 2007; DiNardo, 2013), yet 
allogeneic transfusions are identified by The Joint Commission as one of the 
most overused procedures in healthcare (jointcommission.org) and are 
pervasively associated with adverse outcomes in many surgical settings (Koch et 
al., 2006; Chelemer et al., 2002). In some patients, a transfusion may correct a 
physiologic imbalance and yet be associated with worse clinical outcomes 
(Bernard et al., 2009; Glance et al., 2011; Ferraris et al., 2012). A concise 
summary of allogeneic transfusion risks by Goodnough is infection (via agents 
that are routinely tested for, such as human immunodeficiency virus, and agents 
that are not tested for, such as malaria), hemolytic reactions, alloimmunisation, 
medical errors, transfusion-associated acute lung injury, transfusion-associated 
circulatory overload, iron overload, immunomodulation, and storage lesions due 
to the age of transfused products (Goodnough, 2013). Modern medical 
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knowledge and clinical practices place a few of these risks at an all-time low, 
however, new and emerging dangers are a constant threat (Vamvakas and 
Blajchman, 2009; Shander et al., 2016). 
Allogeneic transfusions are associated with adverse outcomes. Populous 
studies of noncardiac surgery patients have found increased mortality and 
morbidity to be associated with both intraoperative (Glance et al., 2011) and 
postoperative transfusions (Abdelsattar et al., 2015). A study of 8,724 cardiac 
surgery patients found perioperative pRBC transfusion to be associated with 
increased infection, morbidity, mortality, and prolonged length of hospital stay 
(Murphy et al., 2007). Death within the first 30 postoperative days was almost 6 
times higher in transfused populations when compared to non-transfused 
populations (Murphy et al., 2007). Shander et al. performed a literature review of 
19 substantial studies evaluating the clinical outcomes of allogeneic pRBC 
transfusions in various patient populations and found that transfusions do little to 
improve the patient condition, undermining their clinical effectiveness (Shander et 
al., 2011a). 
These reported negative risks and outcomes become alarming when the 
large variation in transfusion practices is considered (Shander et al., 2012). 
Studies have shown significant inter-institutional variability in transfusion rates of 
all hemostatic products (Rogers et al., 2009; Bennett-Guerrero et al., 2010; Frank 
et al., 2012). In addition, a large observational study of 102,270 patients showed 
enormous variability in coronary artery bypass graft surgery across a large 
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number of hospitals in the United States (Bennett-Guerrero et al., 2010). In 2011, 
The United States Department of Health and Human Services Advisory 
Committee for Blood Safety and Availability stated that this wide variation is a 
clear indicator of excessive and inappropriate use of transfusions (US 
Department of Health). 
There is poor integration on a national level of scientific evidence with 
recognized guidelines to determine when hemostatic products should be 
transfused (Murphy et al., 2007). Murphy et al. states that pRBC transfusion is 
harmful in almost all cardiac surgery patients as is used today because it is 
difficult to identify those who truly do need transfusion using standard indicators 
(Murphy et al., 2007). For instance, hematocrit level is a common indication in 
critically ill patients, but this trigger is not supported by many studies (Murphy and 
Angelini, 2006; Murphy et al., 2007) because isolated hematocrit levels are poor 
indicators of tissue hypoxia (Torres Filho et al., 2005). Perioperative monitoring 
of hematocrit is also unsupported because it is often invasive (Murphy and 
Angelini, 2006) and equations used to determine blood component levels do not 
always assess oxygen consumption appropriately (Kemming et al., 2002). Lack 
of application of evidence-based indications or noncompliance with existing 
guidelines may also be leading to this excessive and unnecessary administration 
of blood components (Snyder-Ramos et al., 2008). These issues become 
amplified in populations that are at a significant risk for receiving blood 
transfusions, making it imperative to minimize blood loss and set clear 
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transfusion thresholds to assure that pediatric patients specifically receive the 
most effective care (Bateman et al., 2008). 
  
Blood management programs 
Perioperative management of blood products has significantly changed 
over the past decade with the development of blood management programs to 
counteract the negative characteristics of allogeneic transfusions (Shander et al., 
2012). These programs apply an evidence-based, multidisciplinary approach to 
medical and surgical situations to optimize hemoglobin levels and hemostasis in 
order to rationalize and to decrease blood product transfusion, as well as to 
improve patient outcomes (Goodnough and Shander, 2012; sabm.org). 
Programs aim to minimize blood product transfusion by correcting preoperative 
anemia, enhancing perioperative assessment of coagulopathy, reducing 
perioperative bleeding, and including a more rational administration of blood 
products via the development of restrictive transfusion algorithms (Shander et al., 
2012; Spahn et al., 2008). The desire to develop these programs is evidenced by 
studies to determine the appropriateness and effectiveness of blood product 
transfusion strategies (Shander et al., 2011b; de Gast-Bakker et al., 2013) and 
the establishment of The Society for the Advancement of Blood Management in 
2001 to research and educate (sabm.org). 
One analysis summarizes blood management programs in four principles 
(Hohmuth et al., 2014). First, low preoperative red blood cell (RBC) volume due 
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to anemia or the small body size of pediatric patients is a risk factor for blood 
transfusion (Goobie et al., 2016) and has been identified as a predictor of 
morbidity, mortality, and increased length of hospital stay (Spahn et al., 2008). 
Blood management programs should detect, evaluate, and correct low RBC 
values in advance of elective surgery as this will reduce the need for allogeneic 
blood (Boucher and Hannon, 2007). Second, point-of-care testing can quickly 
identify hemostatic abnormalities in regard to coagulation. Testing has shown 
positive outcomes in surgical settings (Meybohm et al., 2013) as it lowers 
perioperative blood loss and therefore decreases the need for transfusion 
products (Hohmuth et al., 2014). Patient-specific protocols must be utilized to 
discontinue drugs that may hinder coagulation (Boucher and Hannon, 2007). 
Third, intraoperative blood loss is unsurprisingly associated with increased death 
risk (Wong and Intragumtornchai, 2006). Blood loss and transfusion rates can be 
minimized with the coordination of interdisciplinary approaches to blood 
conservation; intraoperative blood recovery (Waters, 2004), energy-based 
technologies (Sileshi et al., 2010), and sealant agents (Sileshi et al., 2010) are all 
used to aid in hemostasis and reduce allogeneic transfusion. Lastly, approaching 
blood management as an individualized process helps ensure that each patient 
receives appropriate and excellent care (Hohmuth et al., 2014). Improved 
outcomes are observed in fluid medical atmospheres when physicians provide 
complete, understandable treatment information and patients are free to 
communicate their therapeutic preferences (Friedman et al., 2012). 
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In addition to product safety issues, adverse transfusion outcomes, and 
questionable efficacy of transfusions as previously explained, one analysis 
identifies demand and cost as two other variables shifting the medical community 
towards blood management programs (Hofmann et al., 2011). The demand for 
pRBC transfusion, which is already at an all-time high in most developed nations 
(Hofmann et al., 2011), will only increase when current transfusion practice is 
considered along with potential population aging and growth (Hofmann et al., 
2009). Supply of blood products from an age-restricted donor base will decrease, 
which will accelerate the gap between supply and demand (Hofmann et al., 
2011). The United States is not the only nation with this issue; European studies 
based in both Finland (Ali et al., 2010) and Germany (Greinacher et al., 2011) 
have focused on identifying the causes of and dealing with this demand. A full 
cost assessment of transfusion includes logistics for acquiring blood, lab tests, 
pretransfusion examinations, administration of blood products, postoperative 
monitoring, and treating adverse reactions (Hofmann et al., 2011). A study 
analyzed transfusion in two hospitals and identified transfusion cost per surgical 
patient to be $2,696 and $3,589 (Hofmann et al., 2011), and the annual hospital 
acquisition cost for pRBC alone is greater than $3 billion (US Department of 
Health). Allogeneic transfusion is clearly expensive. 
Hemostatic complications are increasingly and preferably corrected by 
patient-centered blood management programs as opposed to product-centered 
allogeneic transfusion therapies (Shander et al., 2013). The allogeneic 
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transfusion is performed often although it may not always be fully supported, and 
patient blood management is a new frontier in the way hemostatic products are 
used in transfusion medicine (Shander et al., 2013).  
 
Cell Salvage (CS) 
Blood management programs aim to avoid allogeneic transfusion of 
pRBC, and, therefore, allogeneic transfusion related risks. Some interventions 
designed to achieve this goal avoid transfusion altogether; these techniques 
include providing a patient with drugs such as aprotinin and tranexamic acid to 
minimize blood loss (Faraoni et al., 2012; Koster et al., 2015), or agents such as 
erythropoietin and iron to maximize RBC production (Waters, 2004; Carless et 
al., 2010). Other interventions to avoid allogeneic transfusion concentrate on 
transfusing a patient’s own blood that is collected via preoperative donation, 
acute normovolemic hemodilution, or the utilization of CS systems (Waters, 
2004; Carless et al., 2010). This reinfused blood is an autologous transfusion, or 
autotransfusion. The use of preoperative autologous donation is no longer 
recommended (Boulton and James, 2007) because the technique has been 
associated with higher incidence of pRBC transfusion due to iatrogenic anemia 
(Singbartl et al., 2013). 
CS summarizes numerous techniques in which a patient’s blood is 
collected from intraoperative surgical sites or postoperative wounds, processed, 
and autotransfused either intra- or postoperatively (Carless et al., 2010). 
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Indication for CS use has previously been if blood loss was expected to be 20% 
or more of total blood volume (American Association, 1997), but more recent 
analysis suggests that CS should be used when smaller blood loss is expected 
because autologous transfusions are efficacious and cheaper than the allogeneic 
alternative (Esper and Waters, 2011). A multitude of CS devices exist that 
process blood differently (Carless et al., 2010). In addition, salvaged blood can 
be washed in a saline solution or unwashed prior to autotransfusion (Ashworth 
and Klein, 2010). Washing removes unwanted byproducts including cytokines, fat 
particles, free hemoglobin, inflammatory mediators, and other tissue and 
chemical debris (Muñoz et al., 2011) but also removes viable coagulation 
proteins and substances that are essential to hemostasis (Wang et al., 2009). 
There is not widespread agreement on which technique is more efficient, but 
unwashed blood is viewed less favorably than washed blood (Carless et al., 
2010) even though numerous studies support the notion that unwashed 
transfusions are safe (Muñoz et al., 2011). Studies of cardiac surgeries show that 
there is no significant difference in allogeneic transfusion rates when comparing 
washed and unwashed blood (Carless et al., 2010). Hemoglobin and hematocrit 
values are lower in shed blood but strong data suggests that collected blood 
contains RBC that are fully viable (Muñoz et al., 2011). 
The systematic use of CS has been shown to significantly reduce the 
incidence of pRBC transfusion in different surgical settings. Carless et al. 
performed a meta-analysis of 75 randomized CS trials that were carried out 
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between 1979-2008. This analysis found that CS reduced overall perioperative 
allogeneic pRBC transfusion by 38% and that the risk of exposure to pRBC 
transfusion was slightly lower in washed cells (Carless et al., 2010). On a large 
scale, CS is favored over allogeneic transfusion because widespread evidence 
suggests that CS does not appear to cause major adverse clinical outcomes 
(Carless et al., 2010).  
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SPECIFIC AIMS 
 
The research and implementation of systematic blood management 
programs are a necessity in today’s blood transfusion climate. CS is one option 
that has shown extreme benefit in certain situations. As more is learned about 
the technique, its benefits, and its limitations, studies based on populations 
undergoing specific surgeries are necessary. Although CS is being used 
nationwide, limited evidence supports the use of the technique to reduce 
allogeneic pRBC transfusions in neonates and children undergoing cardiac 
surgery.  
At BCH in Boston, MA, CS has been systematically used in neonates and 
children undergoing cardiac surgery with CPB since January 2014. This 
retrospective before-and-after study aims to determine changes in the 
transfusion of pRBCs and other hemostatic products, assess the incidence of 
postoperative thrombocytopenia and coagulopathy, and determine changes in 
resource utilization following the implementation of a systematic intraoperative 
CS strategy. CS techniques are beneficial as they reduce the need for allogeneic 
pRBC, but a potential increase in need for other hemostatic products and 
questions regarding pediatric populations suggests that the technique may not be 
efficacious when used all the time. This study aims to determine when CS is 
most appropriately used in pediatric cardiac surgeries. 
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METHODS 
 
Study population 
We performed a retrospective medical chart review to study all neonates 
and children who underwent cardiac surgery with CPB between January 2013 
and December 2014 at BCH. Considering that CS has been systematically 
applied since January 2014, children were separate into a CS group (after 
January 2014) and a control group (before January 2014). Children treated with 
CS before January 2014 were excluded.  
 
Data recorded 
 Demographic data and surgical characteristics were recorded and 
collected from the subject’s medical and anesthesia records, perfusion, and 
CICU records; all data were entered into a computer database (RedCap). Patient 
specific information included: gender, date of birth, diagnosis, date of surgery, 
procedure, surgeon, procedure note, and patient medical history. RACHS was 
used to classify surgical operating procedures based on the surgical complexity. 
Duration of the surgery was defined as the time between skin incision and the 
last surgical stitch. The type of oxygenator, use of modified ultrafiltration (MUF) 
and amount of MUF (in milliliters per kilogram) was recorded. Blood product 
transfusion was defined as any intraoperative exposure to pRBC, FFP, 
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reconstituted whole blood, cryoprecipitate, or platelet concentrates that occurred 
during or after CPB, as well as exposure during the first 48 hours of CICU stay. 
We recorded CPB characteristics including prime volume, CPB duration, aortic 
clamp duration, and duration of deep hypothermic circulatory arrest (DHCA) 
selective cerebral perfusion (SCP). Pre-, intra-, and postoperative blood analyses 
routinely performed (such as standard laboratory tests and blood gases) were 
recorded. In addition, we recorded outcome parameters including duration of 
mechanical ventilation, incidence of postoperative cardiac failure, respiratory 
failure, acute kidney injury, need for renal replacement therapy, neurological 
complication, postoperative extracorporeal membrane oxygenation, length of ICU 
stay, length of hospital stay, mortality in ICU, and in-hospital mortality.	  
During the study period, anesthesia technique and CPB management 
were standardized. The anesthetic technique included midazolam, high-dose 
fentanyl, neuromuscular blockade, and inhaled agent, as tolerated. The CPB 
circuit included a Terumo FX05 oxygenator (Terumo Cardiovascular Systems 
Europe, Bagshot, Surrey, United Kingdom) and a reservoir. CPB flow rates were 
adjusted for hypothermia. Continuous ultrafiltration was performed to effectuate 
hemoconcentration, and zero balance ultrafiltration was not performed. 
Therefore, no additional fluid was added to the CPB circuit in conjunction with 
ultrafiltration. After January 2014, the Continuous Auto Transfusion System 
(Fresenius, Oberursel, Germany) was used in all patients to process the blood 
obtained from the cardiotomy suction during the all CPB duration, and returned to 
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the patient as needed. During the study period, the transfusion algorithm was left 
at the discretion of the surgeon and anesthesiologist in charge.  
 
Statistical analysis 
  Demographic and baseline characteristics were compared between the 
CS group and the historical control group using statistical analysis. Categorical 
variables are expressed as number and percentage, and continuous variables 
are expressed as median and interquartile range. Variables were compared 
between the groups ‘CS’ and ‘control’ using chi-square or Mann-Whitney U test. 
To control for possible confounding among variables, we used multivariable 
logistic regression using backward selection to determine the independent 
predictors for in-hospital mortality using a univariable cut off of P < 0.10 for 
inclusion and P > 0.05 for removal. The results are expressed as regression 
coefficient (B) and standard error (SE), the odds ratio (OR) as a measure of risk, 
the 95% confidence interval (CI), and P-values obtained from the Wald test. 
Statistical analysis was performed using Stata software (version 14.1 for Mac 
OS, Stata Corporation, College Station, Texas). 
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RESULTS 
 
 Among 1228 patients included in the study, 730 were included in the CS 
group and 498 in the control group. When comparing age, weight, risk scores 
(ASA and RACHS), and information regarding CPB, aortic clamping, DHCA, and 
SCP (Table 1), it was found that age was lower in the CS group (7 months (2-52) 
vs. 13 months (3-63), p = 0.049) but no other differences in demographic and 
surgical characteristics were observed between groups.  
Laboratory values of hemoglobin, platelets, and fibrinogen between the 
control and CS group were compared (Table 2). 48 control patients received 
transfused pRBC and 42 CS patients received transfused pRBC (Figure 1 and 
2). 31 control patients and 39 CS patients received perioperative cryoprecipitate 
transfusion (Figure 3). 31 control patients and 39 CS patients received 
perioperative platelets transfusion (Figure 4). The results of our multivariate 
logistic regression analysis showed that age < 12 months (OR: 2.95, 95% CI: 
2.26- 3.84), ASA > 3 (OR: 2.95, 95% CI: 2.26-3.84), RACHS > 3 (OR: 1.78, 95% 
CI: 1.28-2.49), and the use of CS (OR: 0.57, 95% CI: 0.44-0.73) were good 
predictors for total perioperative RBC transfusion (Table 3).  
Table 4 and Figure 5 describe the OR (95% CI) for the effect of CS on 
pRBC, cryoprecipitate, and platelets transfusion. Using univariable analysis, the 
use of CS was associated with a significant reduction in pRBC transfusion (OR: 
0.76, 95% CI: 0.61-0.96, p = 0.021), but a significant increase in cryoprecipitate 
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(OR: 1.37, 95% CI: 1.08-1.76, p = 0.009) and platelets transfusions (OR: 1.37 
95% CI: 1.08-1.76, p = 0.004). However, after adjustment for age < 12 months, 
ASA > 3, and RACHS > 3, the use of CS significantly reduced RBC transfusion 
(OR: 0.57, 95% CI: 0.44-0.73, p < 0.001), with no effect on cryoprecipitate (OR: 
1.08, 95% CI: 0.83-1.41, p = 0.543) and platelets transfusions (OR: 1.05, 95% CI: 
0.81-1.36, p = 0.694).  
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Table 1. Comparison of demographic and surgical characteristics between 
controls and children exposed to CS.  
Characteristic measured Controls 
(n=498) 
CS 
(n=730) 
P value 
age (months) 13 (3-63) 7 (2-52) 0.049 
body weight (kilograms) 8.9 (4.6-19.2) 6.7 (3.9-15.7) 0.009 
ASA  <0.001 
2 12 (2) 16 (2)  
3 250 (51) 223 (31)  
4 224 (46) 472 (66)  
5 3 (1) 6 (1)  
RACHS 0.006 
1 40 (8) 39 (5)  
2 229 (46) 358 (49)  
3 156 (32) 221 (30)  
4 51 (10) 56 (8)  
5 14 (3) 19 (3)  
6 7 (1) 35 (5)  
CPB time (minutes) 119 (75-160) 120 (84-163) 0.433 
aortic clamp (yes/no) 440 (88) 631 (86) 0.324 
aortic clamp time (minutes) 78 (51-114) 73 (51-105) 0.426 
DHCA (yes/no) 125 (17) 66 (13) 0.066 
DHCA time (minutes) 25 (9-46) 15 (7-27) 0.001 
SCP (yes/no) 24 (5) 73 (10) 0.001 
SCP time (minutes) 71 (28-92) 49 (40-80) 0.290 
CPB prime (milliliter per killogram) 38 (29-55) 41 (28-63) 0.133 
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Table 2. Comparison of laboratory values between controls and children 
exposed to CS.  
 
 
 
Blood product 
(when recorded) 
Controls 
(n=498) 
Cell-Saver 
(n=730) 
P value 
hemoglobin 
(baseline) 
13.0 (11.9-14.2) 13.2 (12.0-14.8) 0.024 
hemoglobin 
(ICU admittance) 
12.4 (11.1-14.0) 13.0 (11.7-14.4) <0.001 
hemoglobin 
(day 1) 
12.4 (11.1-13.9) 13.0 (11.8-14.3) <0.001 
platelet count 
(baseline) 
297 (234-368) 298 (130-381) 0.993 
platelet count 
(ICU admittance) 
166 (118-226) 179 (127-248) 0.154 
platelet count 
(day 1) 
169 (122-230) 177 (123-344) 0.409 
fibrinogen 
(baseline) 
275 (240-380) 306 (130-386) 0.879 
fibrinogen 
(ICU admittance) 
276 (231-366) 281 (227-348) 0.969 
fibrinogen 
(day 1) 
261 (209-311) 263 (199-330) 0.930 
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Table 3. Multivariate logistic regression analysis to predictors associated 
with total pRBC transfusion.  
 
 B (SE) OR 95% CI P value 
ASA > 3 1.08 (0.14) 2.95 2.26-3.84 <0.001 
age < 12 months 0.44 (0.13) 1.56 1.22-2.00 <0.001 
RACHS > 3 0.58 (0.17) 1.78 1.28-2.49 0.001 
CS (yes/no) -0.56 (0.13) 0.57 0.44-0.73 <0.001 
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Table 4. OR for blood product transfusion in children treated with 
intraoperative CS before and after adjustment for risk factors. 
 
 
 
* Adjusted for ASA>3, Age < 12 months, RACHS>3 
!
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able 4. OR for blood product transfu ion n children t ated with 
i traoperative CS before and after adjustment for risk factors.  
 
 
 
* Adjusted for ASA>3, Age < 12 months, RACHS>3 
 
Blood Product OR 
(95% CI) 
P value 
 
 *OR  
(95% CI) 
*P value 
intraoperative pRBC (yes/no) 0.88 (0.68-1.15) 0.356 
0.70 
(0.53-0.93) 0.014 
postoperative pRBC (yes/no) 0.80 (0.63-1.02) 0.075 
0.64 
(0.49-0.83) 0.001 
total pRBC (yes/no) 0.76 (0.61-0.96) 0.021 
0.57 
(0.44-0.73) <0.001 
intraoperative cryoprecipitate 
(yes/no) 
1.57 
(1.22-2.01) <0.001 
1.24 
(0.95-1.63) 0.108 
postoperative cryoprecipitate  
(yes/no) 
0.70 
(0.44-1.13) 0.143 
0.60 
(0.37-0.98) 0.040 
total cryoprecipitate  (yes/no) 1.37 (1.08-1.76) 0.009 
1.08 
(0.83-1.41) 0.543 
Intraoperative platelet (yes/no) 1.58 (1.26-2.00) <0.001 
1.26 
(0.98-1.63) 0.074 
Postoperative platelet (yes/no) 0.65 (0.45-0.93) 0.019 
0.54 
(0.37-0.78) 0.001 
total platelet (yes/no) 1.37 (1.08-1.76) 0.004 
1.05 
(0.81-1.36) 0.694 
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Figure 1: Volume of pRBC transfused in controls and children treated with 
CS. 
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Figure 2: Incidence of pRBC transfusion in controls and children treated 
with CS. 
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Figure 3: Incidence of cryoprecipitate transfusion in controls and children 
treated with CS. 
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Figure 4: Incidence of platelet transfusion in controls and children treated 
with CS. 
 
	  28 
Figure 5: OR for the effect of CS on perioperative blood product 
transfusion. 
 
 
*Multivariate logistic regression adjustment for age < 12 months, ASA > 3, and 
RACHS>3 
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DISCUSSION 
Principle findings 
Our retrospective study analyzed 1,228 pediatric patients who underwent 
cardiac surgery with CPB over a two-year period (January 2013-December 2014) 
at BCH. This study focused on the effect CS usage on perioperative blood 
product transfusion. Analysis of the whole study population demonstrates that the 
use of CS was associated with a significant reduction in pRBC transfusion but a 
significant increase in cryoprecipitate and platelets transfusions. However, when 
adjusted for predictors of perioperative hemostatic product transfusion (a high 
risk population of age < 12 months, ASA > 3, RACHS > 3), we found that the 
utilization of CS significantly reduced pRBC transfusion with no effect on 
cryoprecipitate and platelets transfusions.  
 
Transfusion in cardiac surgery 
Cardiac procedures in general consume more than 80% of hemostatic 
products transfused during all surgeries (Ferraris et al., 2007; McQuilten et al., 
2014). Allogeneic transfusions have inherent risks, are associated with adverse 
outcomes, and lack extensive guidelines for widespread, systematic practice. 
These factors make transfusions dangerous to patients. There is widespread 
understanding throughout the medical community that further studies are needed 
to determine the true necessity for allogeneic blood transfusions (Murphy et al., 
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2007). Prevalent negativity surrounding allogeneic transfusions is steadily 
leading the medical community to research and potentially implement a more 
restrictive strategy for transfusion (Frank et al., 2015). In 2011, the Society of 
Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists jointly 
released updated guidelines on blood conservation management in an attempt to 
better transfusion therapy (Ferraris et al., 2011). Numerous organizations 
included the Joint Commission, the American Medical Association, the American 
Society of Anesthesiology, and the World Health Organization are also vocal in 
regards to this goal (Practice guidelines, 2015).   
The enhanced blood loss during cardiac surgeries demonstrates the need 
for blood management programs specifically for these patients. CS is one 
program that may aid these patients as it significantly reduces exposure to 
allogeneic blood products in cardiac procedures, specifically pRBC transfusion 
(Wang et al., 2009). One meta-analysis of 13 cardiac surgery trials shows that 
CS reduced allogeneic transfusion by 23% with an average saving of one unit of 
allogeneic blood per patient (Carless et al., 2010). Many randomized controlled 
trials support the use of CS to reduce blood transfusions in cardiac surgery 
(Dietrich et al.,1989; Daane et al., 2003; Damgaard and Steinbrüchel, 2006; Goel 
et al., 2007); as a result, CS techniques are increasingly included in the 
perioperative management of patients undergoing cardiac surgery (Wang et al., 
2009). On the other hand, some studies do demonstrate that routine CS does not 
reduce allogeneic blood transfusion (Klein et al., 2008). A meta-analysis reported 
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that the efficacy of cell saver to reduce blood product transfusion requirements 
varies depending on the timing and the way the cell saver is used intra- and 
postoperatively (Wang et al., 2009). 
Some controversies exist regarding a potential increased bleeding risk, an 
increased incidence of thrombocytopenia, and coagulopathy in patients exposed 
to CS pRBC (Djaiani et al. 2007; Rubens et al., 2007). Washing the CS product 
prior to autotransfusion removes platelets and other essential hemostatic factors 
(Wang et al., 2009) that may need to be transfused allogeneically. Djaiani et al. 
found that patients who received FFP transfusion had a significant increase in 
the amount of autologous pRBC transfused from processed cardiotomy blood 
(Djaiani et al. 2007). This suggests that CS may lead to increased bleeding 
secondary to a critical loss of coagulation factors (Despotis et al., 1996; Djaiani et 
al. 2007). Rubens et al. suggests that there may be little justification to 
systematic CS usage as trials found that CS processing of cardiotomy blood 
leads to increased postoperative bleeding and, therefore, need for allogeneic 
blood products (Rubens et al., 2007). The results observed in those two 
prospective studies were discussed in a systematic review with meta-analysis 
published by Wang et al. in 2009 (Wang et al., 2009). Based on current 
evidence, the authors suggest that the use of a cell saver reduces exposure to 
pRBC transfusion for patients undergoing cardiac surgery. However, 
subanalyses also suggest that the use of CS may be beneficial only when it is 
used for shed blood and/or residual blood or during the entire operative period. 
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Processing cardiotomy suction blood with a CS only during CPB has no 
significant effect on blood conservation and increases FFP transfusion. 
 
CS in pediatric populations 
Neonates and children undergoing cardiac surgery with CPB are at an 
increased risk of bleeding (Willems et al., 2010); when undergoing cardiac 
surgery this group is at a unique risk for allogeneic blood product, and therefore 
benefit from blood management programs. Little data regarding CS usage in 
pediatric cardiac surgical cases exists, mostly because technical limitations have 
prevented CS usage for pediatric patients (Booke et al., 1999; Golab et al., 
2008). Recent advancements have made CS usage possible for the small 
volume requirements of this population (Cholette et al., 2013). Observational 
studies suggest that CS can be safely used to decrease allogeneic transfusion in 
non-cardiac surgeries of children (Dahmani et al., 2000) and neonates and small 
infants (Orliaguet et al., 2003). A study that used an alternative autotransfusion 
system to administer pRBC to neonates undergoing heart surgery found 
autotransfusion to be beneficial in this population (Liu et al., 2007). One 
prospective nonrandomized cohort study describing postoperative transfusion of 
CS in a dedicated pediatric system exists. Although CS blood was only available 
for autotransfusion for 6 hours after its collection, this study found that CS was a 
safe and effective method to reduce postoperative allogeneic pRBC transfusion 
(Golab et al., 2008). In a recent study, Cholette et al. reported that the 
	  33 
administration of cell salver salvaged blood, stored at the bedside during 24 
hours, significantly reduced the number of red blood cells (RBCs) and coagulant 
products transfused in neonates and infants undergoing open-heart surgery 
(Cholette et al., 2013). 
 
Comparison of data and literature 
 Our study follows trends that Golab et al. and Cholette et al. have 
described in similar patients. This study adds important information to a 
necessary but currently inadequate database on the efficacy of CS in pediatric 
patients undergoing cardiac surgery. This population is at an inherent risk for 
hemostatic products, yet the most effective methods for blood product restitution 
are unknown. Our study provides data that will help further knowledge regarding 
CS utilization. In addition, our study supports the finding reported in the adult 
population, confirming that if the systematic use of CS to proceed cardiotomy 
suction during CPB may increase the risk of non-pRBC transfusions, its uses in 
high risk neonates and children could help decrease the requirement of pRBC 
without increasing the need for cryoprecipitate and platelets transfusions.  
  
Limitations 
 We performed a retrospective analysis of data collected from a single-
centre departmental database and the results can only be applied to our study 
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population. While strong associations were found between CS utilization and 
pRBC transfusion rates, the present results should be considered as preliminary 
and need to be validated in a much larger cohort. In addition, the retrospective 
nature of this study could not guarantee the absence of bias. In order to 
decrease this bias as much as possible, we performed univariable and 
multivariable regression analyses, which are recommended in the case of 
retrospective design. This study presents data that should be regarded as a 
segment of a much larger conversation.  
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CONCLUSION 
 
The use of CS in neonates and children undergoing cardiac surgery with 
CPB significantly reduced the incidence of allogeneic RBC transfusion. Although 
the systematic use of CS in adults has been associated with an increased 
incidence of non-RBC transfusions, the use of CS in a high risk pediatric 
population (i.e. age < 12 mo, ASA > 3, RACHS > 3) was associated with a 43% 
reduction of RBC transfusion without an increase in cryoprecipitate and platelet 
transfusions.  
 
Implications for future research 
Future studies will identify other biomarkers that are associated with 
transfusion. These markers may include neutrophil to lymphocyte ratio or lactate 
levels, and will be analyzed by reevaluating medical charts. In addition, 
intraoperative equipment such as mechanical pumps may cause hemolysis with 
increased flow and may need to be analyzed. Comprehensively evaluating 
transfusion predictors will better blood management programs for all patients, 
with a specific emphasis on our study population. 
Other studies are required to identify transfusion cost-saving maneuvers. 
We may obtain resource utilization data from individual hospital bills or the 
Pediatric Health Information System, an administrative database coordinated 
through the Children’s Hospital Association that collects information from the 
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hospital bills from more than 40 children’s hospitals in the United States, to 
analyze cost differences between allogeneic and autologous transfusions. This 
financial information will evaluate if CS is financially advantageous.  
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